Clinical trial
A Phase III Randomized, Double-Blind, Controlled Study of the Use of Anti-HIV…
NCT00000751 · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), NIH · Completed
Key facts
| NCT number | NCT00000751 |
|---|---|
| Title | A Phase III Randomized, Double-Blind, Controlled Study of the Use of Anti-HIV Immune Serum Globulin (HIVIG) for the Prevention of Maternal-Fetal HIV Transmission in Pregnant Women and Newborns Receiving Zidovudine (AZT) |
| Official title | A Phase III Randomized, Double-Blind, Controlled Study of the Use of Anti-HIV Immune Serum Globulin (HIVIG) for the Prevention of Maternal-Fetal HIV Transmission in Pregnant Women and Newborns Receiving Zidovudine (AZT) |
| Lead sponsor | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), NIH |
| Collaborators | National Institute of Allergy and Infectious Diseases (NIAID) NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infections, Pregnancy |
| Intervention type | Drug |
| Interventions | Anti-HIV Immune Serum Globulin (Human), Globulin, Immune, Zidovudine |
| Enrollment | 1,600 |
| Completion | Aug 1, 2007 |
| First posted | Aug 31, 2001 |
| Last update posted | Sep 30, 2008 |
| Countries | Puerto Rico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: